RegeneRx begins patient enrolment in US for ARISE-2 trial of RGN-259 to treat dry eye syndrome

US-based clinical-stage drug development company RegeneRx has begun patient enrolment in its Phase III ARISE-2 trial of RGN-259 (Thymosin beta 4) to treat dry eye syndrome, neurotrophic keratopathy (NK), and other corneal disorders.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news